Free Access
Further reading
Book Editor(s):Barry J. Maron MD,
Lisa Salberg,
Barry J. Maron MD
Director, Hypertrophic Cardiomyopathy Center
Minneapolis Heart Institute Foundation, Minneapolis, MN, USA
Adjunct Professor of Medicine, Tufts University School of Medicine, Boston, MA, USA
Adjunct Professor of Medicine, Mayo Medical School, Rochester, MN, USA
Search for more papers by this authorLisa Salberg
Chief Executive Officer and Founder
Adjunct Professor of Medicine, Tufts University School of Medicine, Boston, MA, USA
Search for more papers by this author
First published: 20 January 2014
References
- Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013; 381: 242–255.
- Maron BJ, Braunwald E. Evolution of hypertrophic cardiomyopathy to a contemporary treatable disease. Circulation 2012; 126: 1640–1644.
- Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 191–200.
- Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012; 60: 705–715.
- Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rawkowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:e783–e831. J Am Coll Cardiol 2011; 58: e212–e260.
- Maron BJ, Olivotto I. Hypertrophic cardiomyopathy. In Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th ed, DK Mann, DR Zipes, P Libby, RO Bonow (Eds). Elsevier, Philadelphia (2013).
- Maron BJ, Spirito P, Shen W-K, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NAM III, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405–412.
- Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NAM III, Shannon KM, Ashley EA, Day SM, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger SN, Maron MS, Link MS. Prevention of sudden cardiac death with the implantable cardioverter-defibrillator in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 2013; 61(14): 1527–1535.
- Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RHM, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy over 60 years of age. Circulation 2013; 127: 585–593.
- Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010; 121: 445–456.
- Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res 2011; 108: 743–750.
- Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter AM Jr, Krauss MD, Maron MS, Mitten MJ, Roberts WO, Puffer JC. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: update 2007. A scientific statement from the American Heart Association, Nutrition, Physical Activity, and Metabolism Council. Circulation 2007; 115: 1643–1655.
- Maron BJ. Hypertrophic cardiomyopathy centers. Am J Cardiol 2009; 104: 1158–1159.
- Chan RH, Maron BJ, Olivotto I, Assenza GE, Lesser JR, Haas T, Gruner C, Crean A, Rakowski H, Udelson JE, Rowin E, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Prognostic utility of contrast-enhanced cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: an international multicenter study (Abstract). Circulation 2012; 126:A13139.
- Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ. Prevalence, clinical profile and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114: 216–225.
- Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies. An American Heart Association Scientific Statement. Circulation 2006; 113: 1807–1816.
- Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114: 2232–2239.
- Maron BJ. The 2009 international hypertrophic cardiomyopathy summit. Am J Cardiol 2010; 105: 1164–1168.
10.1016/j.amjcard.2009.12.021 Google Scholar
- Maron BJ. Dr. Gunnar Thor Gunnarsson and hypertrophic cardiomyopathy: what “giving back” means. Am J Cardiol 2010: 105: 277–278.
- Maron BJ, Lever H. In defense of antimicrobial prophylaxis for prevention of infective endocarditis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 2339–2340.
- Maron BJ. Sudden death in young athletes. N Engl Med 2003; 349: 1064–1075.
- Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation 2006; 114: 1633–1644.
- Maron BJ. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 2007; 116: 196–206.
- Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. Task force 4: Hypertrophic cardiomyopathy and other cardiomyopathies, mitral valve prolapse, myocarditis and Marfan syndrome. In 36th Bethesda conference. Eligibility recommendations for competitive athletes with cardiovascular abnormalities (Maron BJ, Zipes DP). J Am Coll Cardiol 2005; 45: 1340–1345.
- Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the U.S., 1980–2006. Circulation 2009; 119: 1085–1092.
- Maron BJ, Zipes DP. 36th Bethesda conference: eligibility recommendations for competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol 2005; 45: 1312–1375.
- Hauser RG, Maron BJ. Lessons from the failure and recall of an implantable cardioverter defibrillator. Circulation 2005; 112: 2040–2042.
- Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112: 855–861.
- Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. Am Coll Cardiol. 2005; 45: 1251–2358.
- Maron BJ. Surgery for hypertrophic obstructive cardiomyopathy: alive and quite well. Circulation 2005; 111: 2016–2018.
- Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. Am Coll Cardiol 2005; 46: 470–476.
- Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, Siu S, Ralph-Edwards A, Rakowski H. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005; 111: 2033–2041.
- Nishimura RA, Holmes DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004; 350: 1320–1327.
- Maron BJ. Hypertrophic cardiomyopathy: an important global disease (editorial). Am J Med 2004; 116: 63–65.
- Maron BJ, Barry JA, Poole RS. Pilots, hypertrophic cardiomyopathy and issues of aviation and public safety. Am J Cardiol 2004; 93: 441–444.
- Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, Nishimura RA. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44: 2044–2053.
- Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol 2003; 92: 1183–1186.
- Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308–1320.
- Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104: 2517–2524.
- Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation 1995; 92: 785–789.
- Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778–1785.
- Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999; 99: 2927–2933.
- Maron BJ, Braunwald E. Eugene Braunwald MD and the early years of hypertrophic cardiomyopathy: a conversation with Dr. Barry J. Maron. Am J Cardiol 2012; 109: 1539–1547.
- Maron BJ, Seidman CE, Ackerman MJ, Towbin JA, Maron MS, Ommen SR, Nishimura RA, Gersh BJ. How should hypertrophic cardiomyopathy be classified?: What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. Circ Cardiovasc Genet 2009; 2: 81–85.
- Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation 2010; 122: 2441–2449.
- Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46: 480–487.
- Ho CY. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation 2010; 122: 2430–2440.
- Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (−) family members in hypertrophic cardiomyopathy. Am J Cardiol 2011; 107: 604–608.
- Maron BJ, Casey SA, Haas TS, Kitner CL, Garberich RF, Lesser JR. Hypertrophic cardiomyopathy with longevity to 90 years or older. Am J Cardiol 2012; 109: 1341–1347.
- Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010; 3: 574–579.
- Spirito P, Autore C, Rapezzi C, Bernabò P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, Estes NA, Barillà CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009; 119: 1703–1710.
- Maron BJ, Yacoub M, Dearani JA. Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. Eur Heart J 2011; 32: 1055–1058.
- ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, Serruys PW. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail 2010; 3: 362–369.
- Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ. Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009; 54: 220–228.
- Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295–303.
- Maron MS, Finley JJ, Bos JM, Hauser RH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118: 1541–1549.
- Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Res 2012; 14: 13.
- Kramer DB, Kesselheim AS, Salberg L, Brock DW, Maisel WH. Ethical and legal views regarding deactivation of cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy. Am J Cardiol 2011; 107: 1071–1075.
- Lampert R, Salberg L, Burg M. Emotional stress triggers symptoms in hypertrophic cardiomyopathy: a survey of the Hypertrophic Cardiomyopathy Association. Pacing Clin Electrophysiol 2010; 33: 1047–1053.
- Lara AA, Salberg L. Patient advocacy: what is its role? Pacing Clin Electrophysiol 2009; 32(Suppl. 2): S83–S85.
10.1111/j.1540-8159.2009.02392.x Google Scholar
- Brimacombe M, Walter D, Salberg L. Gender disparity in a large nonreferral-based cohort of hypertrophic cardiomyopathy patients. J Womens Health (Larchmt) 2008; 17: 1629–1634.
- Maron BJ, Bonow RO, Salberg L, Roberts WC, Braunwald E. The first patient clinically diagnosed with hypertrophic cardiomyopathy. Am J Cardiol 2008; 102: 1418–1420.
- Salberg L. GINA update. J Cardiovasc Transl Res 2008; 1: 9–10.
- Reineck, E, Rolston B, Bragg-Gresham J, Salberg L, Baty L, Kumar S, Wheeler MT, Ashley E, Saberi S, Day SM. Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy. Am J Cardiol 2013; 111(7): 1034–1039.
- Olivotto I, Maron BJ, Tomberli B, Appelbaum E, Salton C, Haas TS, Gibson CM, Nistri S, Servettini E, Chan RH, Udelson JE, Lesser JR, Cecchi F, Manning WJ, Maron MS. Impact of obesity on the phenotype and clinical course of hypertrophic cardiomyopathy. J Am Coll Cardiol 2013; 62: 449–457.
- Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, Lurie PR, Orav EJ, Towbin JA. Epidemiology and cause specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007; 115: 773–781.
- Maron BJ, Casey SA, Haas TS, Kitner C, Garberich R. Hypertrophic cardiomyopathy with longevity to 90 years or older. Am J Cardiol 2012; 109: 1341–1347.
- Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RHM, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy over 60 years of age. Circulation 2013; 127: 585–593.
